| |
Cortistatin 14, human, rat  |
|
|
| Cat. No. |
Size |
Price |
Figures |
|---|
RP10972-0.5 mg
| 0.5 mg | $ 66.50 | HPLC: 20080903051119 (PDF)
MS: 20080903051219 (PDF)
References:
- Benso A, et al. Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans. J. Endocrinol. Invest. Jul 2003; 26(7): 599-603.
- Broglio F, et al. Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans. J. Clin. Endocrinol. Metab. Aug 2002; 87(8): 3783-3790.
- Cassoni P, et al. Cortistatin-14 inhibits cell proliferation of human thyroid carcinoma cell lines of both follicular and parafollicular origin. J. Endocrinol. Invest. Apr 2002; 25(4): 362-368.
|
|---|
| Full Name | | Cortistatin 14, human, rat |
|
| Alias |
CST-14 |
Sequence
(one-letter code) |
PCKNFFWKTFSSCK | Sequence
(three-letter code) | {PRO}{CYS}{LYS}{ASN}{PHE}{PHE}{TRP}{LYS}{THR}{PHE}
{SER}{SER}{CYS}{LYS} |
|---|
| Chemical Bridge | Disulfide bridge: Cys2-Cys13. |
|---|
| Description | Cortistatin 14 is a somatastatin-like neuropeptide with neuronal depressant and sleep modulating properties. Cortistatin 14 is present primarily in the cortex and hippocampus. In the hippocampus, cortistatin 14 inhibits pyramidal cell firing and co-exists with GABA. To determine if cortistatin-14 would impair retention, saline or cortistatin 14 was injected intracerebroventricularly after footshock avoidance training into each of a group of CD-1 mice. After one week, training was resumed to determine the effect of cortistatin 14 on retention. Cortistatin 14 was found to impair retention relative to the control group at doses of 0.5-5.0 micrograms. |
|---|
| Formula | C81H113N19O19S2 |
|---|
| M.W. | 1721.01 |
|---|
| Cas | 186901-48-4 |
|---|
| Purity | > 95% |
|---|
| Storage | Store the peptide at -20°C. Keep container tightly closed.
|
| * For Non-Clinical Research Use Only *
Our customer service is available 24 hours a day, Monday through Friday. You may contact us any time for assistance.
|
|
